U.S. markets closed
  • S&P Futures

    3,364.25
    -18.75 (-0.55%)
     
  • Dow Futures

    27,215.00
    -150.00 (-0.55%)
     
  • Nasdaq Futures

    11,533.00
    -55.00 (-0.47%)
     
  • Russell 2000 Futures

    1,575.20
    -13.80 (-0.87%)
     
  • Crude Oil

    38.82
    -0.75 (-1.90%)
     
  • Gold

    1,908.20
    -3.70 (-0.19%)
     
  • Silver

    24.42
    -0.15 (-0.59%)
     
  • EUR/USD

    1.1781
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    0.7780
    -0.0230 (-2.87%)
     
  • Vix

    33.35
    +0.89 (+2.74%)
     
  • GBP/USD

    1.3034
    -0.0007 (-0.05%)
     
  • USD/JPY

    104.4300
    -0.0640 (-0.06%)
     
  • BTC-USD

    13,706.32
    +11.03 (+0.08%)
     
  • CMC Crypto 200

    271.54
    +10.25 (+3.92%)
     
  • FTSE 100

    5,728.99
    -63.02 (-1.09%)
     
  • Nikkei 225

    23,417.17
    -68.63 (-0.29%)
     

Alnylam???s Share Price Rises YTD on Pipeline Developments

Zacks Equity Research
·4 mins read

Shares of Alnylam Pharmaceuticals Inc. ALNY have increased 14.8% year to date compared with the industry’s growth of 8.2%. This growth can be attributed to the following developments.

In March 2020, the European Commission approved Givlaari for the treatment of AHP in patients aged 12 years or older. The drug will be available as a subcutaneous injection. In November 2019, the FDA approved Givlaari (givosiran injection) for subcutaneous use for the treatment of adults with acute hepatic porphyria (AHP). 

In April 2020, Alnylam announced that it completed the rolling submission of the new drug application (NDA) seeking approval for lumasiran as a treatment for primary hyperoxaluria type 1 in the United States. The company also filed a marketing authorization application (MAA) seeking approval for the candidate in the same indication in Europe. In May, the FDA granted priority review to theNDA. A decision from the FDA is expected by Dec 3, 2020.Regulatory applications for lumasiran included positive data from the pivotal ILLUMINATE-A study. Data from the study showed that PH1 patients treated with the candidate met the primary efficacy endpoint of percent change from baseline relative to placebo. The study also achieved statistically significant results for all six tested secondary endpoints, including the proportion of patients achieving a near-normalization or normalization of urinary oxalate.There is a huge unmet need in PH1 and the potential approval of the drug will be a big boost.

In April 2020, the FDA granted a Fast Track designation to vutrisiran for the treatment of polyneuropathy of hATTR amyloidosis in adults. The Fast Track status will help Alnylam submit a rolling NDA for vutrisiran.

In April 2020, Alnylam and The Blackstone Group entered into a broad strategic collaboration.The collaborationwill support Alnylam’s advancement of innovative RNAi medicines with up to a $2-billion investment from Blackstone. Alnylam believes that the deal with Blackstone will make it self-sustainable. The Blackstone investment isalso likely to accelerate the commercial potential of Alnylam’s rapidly advancing product portfolio and support the development and delivery of promising medicines.

Alnylam and partner Vir Biotechnology announced the identification of a development candidate, VIR-2703 (ALN-COV), targeting SARS-CoV-2 for the treatment of COVID-19 in May 2020. The companies plan to meet with the FDA to discuss a potential accelerated path for filing an investigational new drug application to initiate a clinical study to evaluate the candidate at or around 2020-end.

Alnylam Pharmaceuticals, Inc. Price

 

Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. Price

Alnylam Pharmaceuticals, Inc. price | Alnylam Pharmaceuticals, Inc. Quote

Zacks Rank and Stocks to Consider

Alnylam is a Zacks Rank #3 (Hold) stock, presently.

Some better-ranked stocks in the biotech sector are AkceaThrapeuticss Inc. AKCA,  Axcella Health Inc. AXLA and Aytu BioScience Inc. AYTU, all carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Akcea’s loss per share estimates have narrowed from $2.07 to $1.37 for 2020 and from $2.46 to $1.85 for 2021 in the past 60 days.

Axcella’s loss per share estimates have narrowed from $1.14 to 79 cents for 2020 and from $3.30 to $3.03 for 2021 in the past 60 days.

Aytu’s loss per share estimates have narrowed from $1.26 to 12 cents for 2020 in the past 60 days.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report
 
Akcea Therapeutics, Inc. (AKCA) : Free Stock Analysis Report
 
Aytu Bioscience, Inc. (AYTU) : Free Stock Analysis Report
 
Axcella Health Inc. (AXLA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research